This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SABCS 2022
Presentations
Presentation Times
Session Info Card
Seagen Development Pipeline
Seagen Development Pipeline
Ladiratuzumab Vedotin | Breast Cancer | Abstract #OT1-03-06
Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Tucatinib | Breast Cancer | Abstract #OT2-16-03
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
Tucatinib | Breast Cancer | Abstract #P4-03-30
Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer